BP-1C Targets Inflammatory Hypoxic Tumor Micro Environment to Counteract ROS Mediated Angiogenesis in Lung Cancer

Author: Ankith Sherapura, B.M. Siddesh, Y.L. Ramachandra and B.T. Prabhakar

Journal Name:

Download PDF

Abstract

Lung Cancer is a prime and defied malignancy tumor with multiple hall marks of cancer. Establishing the treatment strategy for lung cancer is extremely challenging due to aggressive adaptation of cancerous cell to TME. The ROS, inflammation and hypoxia are the major key parameters which are interconnected and interdependent in lung cancer responsible for angiogenesis. Understanding the relationship between these TME parameters could be the advantageous to develop the therapeutic targets. Previously we have reported that, BP-1C induces apoptosis and anti-angiogenesis mediated antitumor properties in both ascites and solid tumor model. Further investigation has identified JAK2/STAT3 signaling mediated regression of lung cancer. Current research postulates that, BP-1C targets pathological features of Lung TME, particularly ROS and hypoxia to counteract lung cancer. The in-vitro study results revealed that, BP-1C reduces hypoxia as verified by EF5, a hypoxic marker and reduced ROS and lipid per oxidation assay with increased Glutathione. Further, reduced pro-inflammatory cytokines such IL-6, IL-1β and TNF-α, as well as angiogenic players such as VEGF, MMP-2 & 9 were evident. The results correlates with earlier findings of BP-1C medicated affect, such as induction of apoptosis and anti-angiogenesis. The current investigation establishes molecular cause of these events induced by BP-1C. The research outcome states that, BP-1C could be developed as an effective target specific molecule to counteract Lung cancer.

Keywords

Lung cancer, ROS, Inflammation, Hypoxia, BP-1C, Angiogenesis

Conclusion

The current investigation postulates the multi-mode approach of the BP-1C in exhibiting its anti-tumor property. The results authenticated the BP-1C counteract both ROS and hypoxia. The BP-1C effectively reduced the ROS and hypoxic TME and its associated angiogenic gene expression. Overall, BP-1C is a potent anti-neoplastic agent with multi-target drug for therapeutic approach of lung cancer.

References

-

How to cite this article

Ankith Sherapura, B.M. Siddesh, Y.L. Ramachandra and B.T. Prabhakar (2023). ¬¬¬BP-1C Targets Inflammatory Hypoxic Tumor Micro Environment to Counteract ROS Mediated Angiogenesis in Lung Cancer. Biological Forum – An International Journal, 15(4): 341-345.